Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPX-351 (daunorubicin + cytarabine)
- Development stage
- Phase 4
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CPX-351 (Vyxeos) is a liposomal formulation containing a fixed 5:1 molar ratio of cytarabine and daunorubicin. Developed by Celator Pharmaceuticals (later acquired by Jazz Pharmaceuticals), it is specifically indicated for the treatment of adults and pediatric patients (1 year and older) with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). The liposomal delivery system maintains the synergistic ratio of the two drugs in the plasma and preferentially delivers them to the bone marrow, where they are taken up by leukemia cells. Cytarabine acts as a nucleoside metabolic inhibitor that interferes with DNA synthesis, while daunorubicin acts as an anthracycline that intercalates DNA and inhibits topoisomerase II.
- Brand names
- Vyxeos
- Other names
- cytarabine and daunorubicin liposomeliposomal cytarabine and daunorubicin
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on CPX-351 (daunorubicin + cytarabine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPX-351 (daunorubicin + cytarabine).